Evidence map›Paper›PMID 38336098›Full record

ReviewIndian heart journal2024

Management of dyslipidemia in special groups.

Jayagopal P B, Prafulla G Kerkar

Open access · goldAbstract readReview
In one paragraph

Review in Indian heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jayagopal P BLakshmi Hospital, Chittur Road, Palakkad, Kerala, India. Electronic address: jaigopallakshmi@gmail.com.
Prafulla G KerkarSeth G.S. Medical College & KEM Hospital, Mumbai, Maharashtra, India.
JK Lakshmipat University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyslipidemia management in situations like pregnancy, in diseases like rheumatoid arthritis, human immunodeficiency virus (HIV) disease, chronic liver disease, and in the elderly are challenging scenarios. Pregnancy is a contraindication for many drugs. The interaction of various drugs used in HIV infection and rheumatoid arthritis makes it even more difficult to treat with conventional and approved drugs for dyslipidemia. Elderly and chronic renal failure patients often do not tolerate the drugs very well and the data of dyslipidemia management is very different. Lastly, COVID-19 is a unique scenario where clear information is yet to be provided. In this manuscript, the current understanding and available data on the treatment of dyslipidemia in these special situations are discussed.

Indexed as

Arthritis, RheumatoidDyslipidemiasHIV InfectionsKidney Failure, ChronicRenal Insufficiency, ChronicAgedFemaleHumansPregnancyCKD dyslipidemiaHIV dyslipidemiaPregnancy dyslipidemia

Identifiers

PMID38336098
PMCPMC11019317
OpenAlexW4391656476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.